All Posts
  • Interviews
1 min read

Bag of Tr1Xs: Off-the-Shelf Type 1 Treg Shows Phase I Promise for GvHD

On this page

Share

In a clinical first, Tr1X Bio showed immune reconstitution and engraftment for allogeneic Tr1 cell therapy, establishing clinical safety and efficacy

Related Articles

Explore posts connected to this topic

View Resources

Tr1X Presents First Clinical Data Demonstrating Proof of Safety and Proof of Mechanism With Allogeneic Off-the-Shelf Tr1 Regulatory T Cell Therapy TRX103

First clinical data from Phase 1 dose-escalation study in patients undergoing HLA-mismatched hematopoietic stem cell transplantation (HSCT). TRX103 demonstrated exceptional...

  • Press Releases

The BioHub Podcast with David de Vries, Co-Founder, CEO, discussing Tr1X’s pipeline of Type-1 regulatory T cells

The BioHub Podcast with David de Vries, Co-Founder, CEO, discussing

  • Videos

Scaling Smarter: a Case Study in Overcoming Cell Therapy Manufacturing & Regulatory Hurdles

Cell & Gene Therapy Insights Webinar titled "Scaling Smarter: a
  • Videos

First clinical data from Phase 1 dose-escalation study in patients

  • Press Releases

The BioHub Podcast with David de Vries, Co-Founder, CEO, discussing

  • Videos
Cell & Gene Therapy Insights Webinar titled "Scaling Smarter: a
  • Videos